FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma.
High [(18)F]-2-fluorodeoxyglucose (FDG)-uptake of primary tumor, assessed by pretreatment positron emission tomography (PET), shows poor overall survival of patients after several therapies in various cancers. An association between FDG-uptake and distant metastasis-free survival in oral squamous cell carcinoma (OSCC) has not been assessed so far. An objective of this study is to investigate an association between FDG-uptake and overall survival of OSCC patients, and to ask whether FDG-uptake is related with distant metastasis-free survival in OSCC. Twenty-four patients who underwent both pretreatment FDG-PET and radical surgery without preoperative therapy were enrolled. We used the maximum standardized uptake value (SUVmax) as FDG-uptake. Overall survival, locoregional recurrence-free survival and distant metastasis-free survival were analyzed by Kaplan-Meier method. In univariate survival analysis, patients with SUVmax>or=12 exhibited significance in both shorter 3-year overall survival (p<0.01) and distant metastasis-free survival (p<0.04) than patients with SUVmax<12. Moreover, by Cox proportional hazards model of multivariate analysis, SUVmax>or=12 was found to be independent of clinical T and N categories, and exhibited significance in both shorter 3-year overall survival (p<0.02) and distant metastasis- free survival (p<0.05) than patients with SUVmax<12. These results suggest that pretreatment FDG-PET is able to provide both non-invasive and effective information for identifying a high- or low-risk group of OSCC patients with distant metastasis.
Suzuki
Hidenori
H
Department of Head and Neck Surgery, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Hasegawa
Yasuhisa
Y
Terada
Akihiro
A
Hyodo
Ikuo
I
Nakashima
Tsutomu
T
Nishio
Masami
M
Tamaki
Tsuneo
T
D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality / Q000556:secondary*; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality; D049268:Positron-Emission Tomography / Q000379:methods; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18